Message #42 From:
NewsBot Date: November 6, 2006 06:00:00 AM
CAMH News Results from St. Jude Medical's Study of Microvolt T-Wave Alternans to be Presented at the 2006 American Heart Association Scientific Sessions
ST. PAUL, Minn., and BEDFORD, Mass.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) and Cambridge Heart, Inc. (OTCBB:CAMH)
today announced that the findings of the Alternans Before Cardioverter
Defibrillator (ABCD) clinical study will be presented at the American
Heart Association (AHA) 2006 Annual Scientific Sessions in Chicago, Ill.
The ABCD clinical study results will be presented at the AHA’s
Late Breaking Clinical Trials sessions on Wednesday, Nov. 15.
The study compared the predictive value of Cambridge Heart’s
noninvasive Microvolt T-Wave Alternans Test™
with standard, invasive electrophysiology tests in identifying patients
at high risk for sudden cardiac death, a condition that kills more than
400,000 Americans each year. The trial was conducted at 42 clinical
centers around the world.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through excellence in
medical device technology and services. The Company has five major focus
areas that include: cardiac rhythm management, atrial fibrillation,
cardiac surgery, cardiology and neuromodulation. Headquartered in St.
Paul, Minn., St. Jude Medical employs approximately 11,000 people
worldwide. For more information, please visit www.sjm.com.
About Cambridge Heart
Cambridge Heart (www.cambridgeheart.com)
is engaged in the development and commercialization of products for the
non-invasive diagnosis of cardiac disease, particularly the
identification of those at risk of sudden cardiac arrest. The Company’s
products incorporate its proprietary Microvolt T-Wave Alternans
measurement technologies, coupled with its patented Spectral Analytic
Method and ultra-sensitive disposable electrodes. Only Spectral
Analytic Method MTWA tests are reimbursed by Medicare under its
National Coverage Policy that covers patients with a wide variety of
cardiac symptoms. Other major insurers in the USA also have coverage
policies for the test. The T-Wave Alternans test is included in the
Guideline for Management of Patients with Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death jointly developed by the American
College of Cardiology (ACC), The American Heart Association (AHA) and
the European Society of Cardiology (ESC).
Forward-Looking Statements
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, regulatory approvals, anticipated future product
launches, revenues, margins, earnings, and market shares. The statements
made by the Company are based upon management’s
current expectations and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. These risks and
uncertainties include market conditions and other factors beyond the
Company’s control and the risk factors and
other cautionary statements described in the Company’s
filings with the SEC, including those described in the Company’s
Annual Report on Form 10-K filed on March 16, 2006 (see Item 1A on pages
15-21) and in the Company’s Quarterly Report
on Form 10-Q filed on August 7, 2006 (see page 31 and Item 1A on page
32). The Company does not intend to update these statements and
undertakes no duty to any person to provide any such update under any
circumstance.
